Oberweis Asset Management Inc. boosted its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 224,920 shares of the medical instruments supplier's stock after acquiring an additional 47,125 shares during the period. Oberweis Asset Management Inc. owned 0.45% of Haemonetics worth $17,562,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in HAE. Boston Trust Walden Corp lifted its holdings in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Haemonetics during the 4th quarter valued at approximately $319,000. Pacer Advisors Inc. boosted its holdings in Haemonetics by 36.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after buying an additional 2,680 shares during the period. Norges Bank purchased a new position in Haemonetics in the 4th quarter valued at approximately $32,803,000. Finally, KBC Group NV raised its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the period. Institutional investors own 99.67% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on HAE. Needham & Company LLC decreased their price objective on Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Raymond James restated a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.
Read Our Latest Stock Analysis on HAE
Haemonetics Price Performance
Shares of NYSE HAE traded up $1.07 during mid-day trading on Tuesday, reaching $63.71. 135,323 shares of the company were exchanged, compared to its average volume of 881,778. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $97.97. The company's 50 day moving average price is $62.80 and its 200 day moving average price is $72.02. The stock has a market capitalization of $3.20 billion, a PE ratio of 25.08, a PEG ratio of 1.11 and a beta of 0.41. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.
Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
